| h-2c776894 | Ferroptosis Inhibition for α-Synuclein Neuroprotection | 0.70 | 0.75 | GPX4 | promoted | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-470ff83e | Microglial Efferocytosis Enhancement via GPR32 Superagonists | 0.70 | 0.50 | CMKLR1 | debated | 2026-04-02 | sda-2026-04-01-gap-014 |
| h-17a2da3f | Astrocyte-Neuron Metabolic Coupling Titration | 0.70 | 0.50 | BDH1 | proposed | 2026-04-17 | SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 |
| h-183fff58 | TDP-43 Pathology Disrupts the HGS-PYGB Autophagy Receptor Cascade in Motor Neuro | 0.70 | 0.72 | TARDBP (TDP-43), HGS, PYGB | proposed | 2026-04-26 | SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c |
| h-21d25124 | TLR4/MyD88/NF-κB Axis Blockade to Interrupt LPS-Mediated Gut-Brain Neuroinflamma | 0.70 | 0.68 | TLR4, MyD88 (MYD88), NF-κB (NFKB1) | promoted | 2026-04-17 | SDA-2026-04-16-gap-20260416-121711 |
| h-f99ce4ca | Purinergic P2Y12 Inverse Agonist Therapy | 0.70 | 0.65 | P2RY12 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-691b42f1 |
| h-0e614ae4 | Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration | 0.70 | 0.70 | SIRT3 | debated | 2026-04-02 | SDA-2026-04-04-gap-epigenetic-reprog-b685190e |
| h-03e31e80 | DAMP-Scavenging Microglial Reset | 0.70 | 0.66 | HMGB1, S100 proteins | proposed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| h-5daecb6e | Microglial Purinergic Reprogramming | 0.70 | 0.58 | P2RY12 | debated | 2026-04-02 | sda-2026-04-01-gap-005 |
| h-4bb7fd8c | Nutrient-Sensing Epigenetic Circuit Reactivation | 0.70 | 0.85 | SIRT1 | promoted | 2026-04-02 | SDA-2026-04-04-gap-epigenetic-reprog-b685190e |
| h-24d53538c7 | Gamma entrainment restores astrocyte-neuron metabolic coupling through Cx43 hemi | 0.70 | 0.65 | GJA1 (connexin 43/Cx43); P2RY1 (P2Y1 receptor); SLC16A3 (MCT | proposed | 2026-04-28 | SRB-2026-04-28-h-bdbd2120 |
| h-19689f6ce7 | GluN2B Tonic Activity Suppresses Glymphatic Perfusion Via Vasomotion Dysregulati | 0.70 | 0.68 | GRIN2B (thalamocortical projection neurons); downstream: NOS | proposed | 2026-04-28 | SRB-2026-04-28-h-var-e2b5a7e7db |
| h-92cfd75109 | NRF2-Mediated Proteostatic Convergence: Shared Oxidative Stress Response Failure | 0.70 | 0.75 | NFE2L2,KEAP1,HMOX1,SQSTM1,PSMB5 | proposed | 2026-04-28 | |
| h-2fe683915d | Lysosomal Acidification Failure: Convergent GBA1/LAMP2A–mediated Autophagy Dysfu | 0.70 | 0.77 | GBA1,LAMP2A,SCARB2,CTSB,CTSD,TFEB | proposed | 2026-04-28 | |
| hyp-lyso-snca-cf55ff | VPS35 Retromer Dysfunction Creates a GCase Trafficking Bottleneck that Synergize | 0.70 | 0.75 | VPS35 | active | 2026-04-28 | |
| hyp-lyso-snca-357729 | Glucosylceramide Accumulation from GCase Deficiency Disrupts SNX5-Mediated Retro | 0.70 | 0.78 | GBA1 | active | 2026-04-28 | |
| 9a0b729f-5882-442b-8 | Test hypothesis 0 | 0.70 | 0.43 | | proposed | 2026-04-27 | |
| ab0857a9-de30-44f8-9 | Test hypothesis 0 | 0.70 | 0.43 | | proposed | 2026-04-27 | |
| aa3eca6b-10a6-4d1e-8 | Test hypothesis 0 | 0.70 | 0.43 | | proposed | 2026-04-27 | |
| c19ee425-4805-41a9-9 | Test hypothesis 0 | 0.70 | 0.43 | | proposed | 2026-04-27 | |
| h-d8e13922ed22 | MAP6-CRMPS cooperative phosphorylation by GSK3β | 0.70 | 0.70 | MAP6/CRMP2 | proposed | 2026-04-26 | paper-34025352 |
| h-f05d11119f | Pericyte-targeted senolysis or senomorphic therapy will benefit only an early bi | 0.70 | 0.64 | PDGFRB, CDKN2A, CDKN1A, BCL2, BCL2L1 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-de5dfc4391 |
| h-6aebb76ee3 | SCFA-Producing Bacterial Depletion → Loss of Neuroprotective Microenvironment | 0.70 | 0.74 | HDAC3, GPR41 (FFAR3), GPR43 (FFAR2), Nrf2, HMOX1 | proposed | 2026-04-22 | sda-2026-04-01-gap-20260401-225155 |
| h-aa1f5de5cd | TREM2 haploinsufficiency dysregulates microglial synaptic surveillance, switchin | 0.70 | 0.22 | TREM2, TYROBP (DAP12), APOE | proposed | 2026-04-22 | SDA-2026-04-02-gap-synaptic-pruning-microglia |
| h-2c8ecd5282 | AAV-Mediated APOE2/APOE3 Gene Delivery to Convert APOE Genotype | 0.70 | 0.78 | APOE | proposed | 2026-04-22 | SDA-2026-04-02-gap-apoe4-targeting |
| h-50d1ee2566 | Ataxin-2 Polyglutamine Expansions Hijack G3BP1 to Form Toxic, Irreversible Stres | 0.70 | 0.68 | ATXN2 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041428-e14e6524 |
| h-2850184c77 | NAD+ Decline and SIRT1 Deficiency Drive Epigenetic Reprogramming Toward Senescen | 0.70 | 0.70 | SIRT1/NAMPT/PPARGC1A | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041439-5f43216e |
| h-4e0d44f33e | TRIM21 as a 'Phase Separation Thermostat' via Catalytic Reversibility | 0.70 | 0.72 | TRIM21 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041423-2d1db50c |
| h-22d6b643b8 | Metabolic Coupling Disruption Sensitizes Motor Neuron mPTP Threshold | 0.70 | 0.72 | PDH (pyruvate dehydrogenase), MCT1/2, PDK, mPTP (ANT/VDAC/Cy | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046 |
| h-49722750cf | m6A RNA Modification as Address Code for Granule Targeting | 0.70 | 0.72 | METTL3, METTL14, FTO, ALKBH5, YTHDF1, YTHDF2, YTHDC1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041428-53b81741 |
| h-53fd55dc89 | FOXO3-Pioneer Factor Complex Stabilizes Heterochromatin Under Oxidative Stress | 0.70 | 0.70 | FOXO3; SIRT1 | proposed | 2026-04-21 | SDA-2026-04-10-gap-20260410-091440 |
| h-db6aa4b1 | Mechanosensitive Ion Channel Reprogramming | 0.70 | 0.55 | PIEZO1 and KCNK2 | debated | 2026-04-02 | sda-2026-04-01-gap-007 |
| h-immunity-50f8d4f4 | CD8+ T-Cell Perforin Pathway as Driver of Neuronal Pyramid Loss | 0.70 | 0.71 | GZMB, PRF1, HLA-E, NKG2D | open | 2026-04-24 | |
| h-66078909 | H2: Indole-3-Propionate (IPA) as the Actual Neuroprotective Effector | 0.70 | 0.65 | PXR (NR1I2), IDO1 | promoted | 2026-04-16 | SDA-2026-04-15-gap-pubmed-20260411-093924-7330920b |
| h-900f7a86 | Granzyme B Inhibition with Serpina3n to Preserve Axonal Integrity Against Cytoto | 0.70 | 0.58 | GZMB | proposed | 2026-04-16 | SDA-2026-04-15-gap-debate-20260410-112400-454036f1 |
| h-f1c69043ea | H5: C9orf72 DPR Dipeptides Corrupt G3BP1 Condensate Properties | 0.70 | 0.76 | C9orf72, G3BP1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041428-4c4414ad |
| h-bba0b5fa | SARM1-Mediated NAD+ Depletion as Terminal Executor of MCT1-Dependent Axon Degene | 0.70 | 0.58 | SARM1, NMNAT2 | promoted | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-170325-196c7ee5 |
| h-a8f0b11bfb | Microglial P2Y12-Dependent Territorial Segregation of Synaptic Inputs | 0.70 | 0.68 | P2RY12 (P2Y12 receptor) | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062128-c84a87d9 |
| h-1e4bba56 | TFEB-Independent Autophagy Bypass | 0.70 | 0.70 | ULK1 | promoted | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc |
| h-8ef34c4c | Lysosomal Calcium Channel Modulation Therapy | 0.70 | 0.75 | MCOLN1 | debated | 2026-04-02 | sda-2026-04-01-gap-011 |
| 9f06a8cc-c784-4260-8 | APOE ε4 Drives Lipid Droplet Accumulation in a Unique Lipid-Associated Microglia | 0.70 | 0.65 | APOE | open | 2026-04-28 | 8f05a068-5b1e-4f32-8ca9-2f375b5dbaf3 |
| h-76888762 | Perforant Path Presynaptic Terminal Protection Strategy | 0.70 | 0.50 | PPARGC1A | debated | 2026-04-02 | sda-2026-04-01-gap-004 |
| h-8196b893 | Axonal RNA Transport Reconstitution | 0.70 | 0.70 | HNRNPA2B1 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-969bd8e0 | Mitochondrial Transfer Pathway Enhancement | 0.70 | 0.30 | MIRO1 | debated | 2026-04-02 | sda-2026-04-01-gap-007 |
| h-21cd4ba1 | Temporal Microglial State Switching | 0.70 | 0.56 | Optogenetic constructs, ion channels | proposed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| h-1fe4ba9b | Complement C1q Mimetic Decoy Therapy | 0.69 | 0.68 | C1QA | debated | 2026-04-02 | sda-2026-04-01-gap-v2-691b42f1 |
| h-ac55ff26 | Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy | 0.69 | 0.40 | ALOX15 | debated | 2026-04-02 | sda-2026-04-01-gap-014 |
| h-bf7edcbc78 | APOE4 hypolipidation and ABCA1 mistrafficking impair cholesterol efflux and seco | 0.69 | 0.68 | ABCA1 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-f4c8357045 |
| h-7de0b0cd41c1 | Endosomal escape determines whether transferred tau becomes pathogenic | 0.69 | 0.67 | RAB7A | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260412-094623-bb7e1c4f |
| h-441b25ba | Palmitoylation-Targeted BACE1 Trafficking Disruptors | 0.69 | 0.60 | BACE1 | proposed | 2026-04-02 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |